THERANOVIR

Problem: Despite the introduction of innovative new cancer therapies like immune checkpoint inhibitors, metastasis, drug resistance, and relapse continue to lead to treatment failures and death of many patients suffering from serious cancers. We are pursuing an innovative new approach that has potential to tackle the challenges presented by uncontrolled cancer progression. Solution: THERANOVIR has uncovered a new cancer pathway, mediated by the Leptin-dependent NRP-1/OBR complex. We have developed a mAb, NOV2, that binds to a form of NRP-1 that appears as cancer progresses and is trafficked to the nucleus causing DNA damage and immune stimulation. NOV2 offers potential as a treatment option for late-stage cancers. Target Markets: Anti-cancer therapy for the oncology market Looking for business opportunities in: We are looking for funding opportunities from VCs, pharma & government grants. We are also open to collaborations with technical experts who can help advance our program. Technology Readiness Level: TRL 5 Prototype Contact info: ZAKIA BELAID-SANDAL zakia.belaid@theranovir.com